摘要
目的比较沙美特罗替卡松吸入剂联合孟鲁司特与单用沙美特罗替卡松吸入剂治疗儿童中度哮喘的有效性。方法将50例儿童中度哮喘病例随机分成两组,治疗组使用沙美特罗替卡松吸入剂,每12h吸入一次联合孟鲁司特,对照组单用沙美特罗替卡松吸入剂,每12h吸入一次,治疗12周后评价两组患儿呼气峰流速值(PEFR)的变化及哮喘日夜症状评分。结果治疗12周后,治疗组与对照组相比,治疗组治疗PEFR值占预计值的百分比与对照组相比明显改善(p<0.05),且治疗组的临床症状评分明显优于对照组(p<0.01)。结论应用沙美特罗替卡松吸入剂和孟鲁司特联合治疗儿童哮喘能更迅速改善临床症状和肺功能,可显著提高儿童哮喘的疗效。
Objective To investigate the therapeutic effects of administration of salmeterol and fluticasone inhalant alone with respect to its combination with montelukast to children asthma. Methods Fifty asthmatic children were divided randomly into two groups, the treatment group subjected to salmeterol and fluticasone inhalant plus montelukast, and the control group to salmeterol and fluticasone inhalant alone. The peak expiratory flow rate （PEFR） value and symptom during the day and at night were evaluated after treatment for 12 weeks. Result Compared with the control group, the number of PEFR in the treatment group were improved significantly after 12 weeks of treatment （p 〈 0.05 ）. , and the clinic scores in the treatment group were significantly lower than that in the control group （p 〈 0.01 ） Conclusion The clinical symptoms and lung function were significantly improved in the group treated with salmeterol and fluticasone inhalant in combination with montelukast as compare to the other treated with salmeterol and fluticasone inhalant alone.
出处
《现代医院》
2007年第3期27-29,共3页
Modern Hospitals
